RT Journal Article
SR Electronic
T1 Clinical and molecular characterization of COVID-19 hospitalized patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.22.20108845
DO 10.1101/2020.05.22.20108845
A1 Benetti, Elisa
A1 Giliberti, Annarita
A1 Emiliozzi, Arianna
A1 Valentino, Floriana
A1 Bergantini, Laura
A1 Fallerini, Chiara
A1 Anedda, Federico
A1 Amitrano, Sara
A1 Conticini, Edoardo
A1 Tita, Rossella
A1 d’Alessandro, Miriana
A1 Fava, Francesca
A1 Marcantonio, Simona
A1 Baldassarri, Margherita
A1 Bruttini, Mirella
A1 Mazzei, Maria Antonietta
A1 Montagnani, Francesca
A1 Mandalà, Marco
A1 Bargagli, Elena
A1 Furini, Simone
A1 ,
A1 Renieri, Alessandra
A1 Mari, Francesca
YR 2020
UL http://medrxiv.org/content/early/2020/11/02/2020.05.22.20108845.abstract
AB Clinical and molecular characterization by Whole Exome Sequencing (WES) is reported in 35 COVID-19 patients attending the University Hospital in Siena, Italy, from April 7 to May 7, 2020. Eighty percent of patients required respiratory assistance, half of them being on mechanical ventilation. Fiftyone percent had hepatic involvement and hyposmia was ascertained in 3 patients. Searching for common genes by collapsing methods against 150 WES of controls of the Italian population failed to give straightforward statistically significant results with the exception of two genes. This result is not unexpected since we are facing the most challenging common disorder triggered by environmental factors with a strong underlying heritability (50%). The lesson learned from Autism-Spectrum-Disorders prompted us to re-analyse the cohort treating each patient as an independent case, following a Mendelian-like model. We identified for each patient an average of 2.5 pathogenic mutations involved in virus infection susceptibility and pinpointing to one or more rare disorder(s). To our knowledge, this is the first report on WES and COVID-19. Our results suggest a combined model for COVID-19 susceptibility with a number of common susceptibility genes which represent the favorite background in which additional host private mutations may determine disease progression.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno fundingsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The GEN-COVID study was approved by the University Hospital of Siena Ethical Review Board (Prot n. 16929, dated March 16, 2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesI declare the availability of all data referred to in the manuscript